Review article · 2013
Development of PI3K inhibitors: lessons learned from early clinical trials
Nature Reviews Clinical Oncology, 10(3), 143–153 · Published 12 February 2013 · DOI 10.1038/nrclinonc.2013.10
In brief
“Development of PI3K inhibitors: lessons learned from early clinical trials” is a 2013 review article by Jordi Ahnert Rodon and 3 co-authors, published in Nature Reviews Clinical Oncology. OpenAlex counts 847 citations as of 21 November 2026, which puts it in the top 1% of works published in 2013 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.
- Citations
- 847
- Most cited in
- 2017 (96)
- Field-weighted impact
- 9.32
- References
- 113
- Authors
- 4
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Rodon, J. A., Dienstmann, R., Serra, V., & Tabernero, J. M. (2013). Development of PI3K inhibitors: lessons learned from early clinical trials. Nature Reviews Clinical Oncology, 10(3), 143–153. https://doi.org/10.1038/nrclinonc.2013.10
MLA 9
Rodon, Jordi Ahnert, et al. “Development of PI3K inhibitors: lessons learned from early clinical trials.” Nature Reviews Clinical Oncology, vol. 10, no. 3, 2013, pp. 143–153. https://doi.org/10.1038/nrclinonc.2013.10.
Chicago
Rodon, Jordi Ahnert, Rodrigo Dienstmann, Violeta Serra, and Josep M. Tabernero. 2013. “Development of PI3K inhibitors: lessons learned from early clinical trials.” Nature Reviews Clinical Oncology 10 (3): 143–153. https://doi.org/10.1038/nrclinonc.2013.10.
Harvard
Rodon, J. A. et al. (2013) ‘Development of PI3K inhibitors: lessons learned from early clinical trials’, Nature Reviews Clinical Oncology, 10(3), pp. 143–153. doi:10.1038/nrclinonc.2013.10.
IEEE
J. A. Rodon, R. Dienstmann, V. Serra, and J. M. Tabernero, “Development of PI3K inhibitors: lessons learned from early clinical trials,” Nature Reviews Clinical Oncology, vol. 10, no. 3, pp. 143–153, 2013, doi: 10.1038/nrclinonc.2013.10.
BibTeX
@article{rodon2013development,
title = {{Development of PI3K inhibitors: lessons learned from early clinical trials}},
author = {Rodon, Jordi Ahnert and Dienstmann, Rodrigo and Serra, Violeta and Tabernero, Josep M.},
journal = {Nature Reviews Clinical Oncology},
year = {2013},
volume = {10},
number = {3},
pages = {143--153},
doi = {10.1038/nrclinonc.2013.10},
url = {https://doi.org/10.1038/nrclinonc.2013.10}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2017 | 96 | |
| 2018 | 70 | |
| 2019 | 61 | |
| 2020 | 55 | |
| 2021 | 55 | |
| 2022 | 41 | |
| 2023 | 33 | |
| 2024 | 28 | |
| 2025 | 31 | |
| 2026 | 24 |
Its field-weighted citation impact is 9.32: it has been cited 9.32 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- PI3K inhibitors
- PI3K/AKT/mTOR pathway
- early clinical trials
- drug safety
- off-target effects
- predictive biomarkers
- drug resistance mechanisms
- translational oncology
Work with this paper
Most-cited papers in Biochemistry, Genetics and Molecular Biology
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTOliver H. Lowry, NiraJ. Rosebrough, A. Lewis Farr and 1 more · Journal of Biological Chemistry · 1951 · 316,470 citations
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingM Bradford · Analytical Biochemistry · 1976 · 256,780 citations
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodKenneth J. Livak, Thomas D. Schmittgen · Methods · 2001 · 184,418 citations
- Molecular Cloning: A Laboratory ManualJoseph Sambrook, Elisabeth Fritsch, Tom Maniatis · UCLA - Biblioteca de Ciencias de la Salud · 1989 · 133,493 citations
- Basic Local Alignment Search ToolStephen F. Altschul, Warren R. Gish, Webb Miller and 2 more · Journal of Molecular Biology · 1990 · 100,529 citations
All highly cited Biochemistry, Genetics and Molecular Biology papers
Questions about this paper
How do I cite this paper in APA style?
Rodon, J. A., Dienstmann, R., Serra, V., & Tabernero, J. M. (2013). Development of PI3K inhibitors: lessons learned from early clinical trials. Nature Reviews Clinical Oncology, 10(3), 143–153. https://doi.org/10.1038/nrclinonc.2013.10
How many times has this paper been cited?
847 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.
Who wrote this paper?
Jordi Ahnert Rodon, Rodrigo Dienstmann, Violeta Serra, Josep M. Tabernero.
What is the DOI of this paper?
10.1038/nrclinonc.2013.10, permanently at https://doi.org/10.1038/nrclinonc.2013.10. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.